Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis

Afatinib, a second-generation, irreversible pan-HER inhibitor, shows better suppression of T790M-positive lung cancer cells than gefitinib in preclinical studies. However, whether the effect of afatinib on T790M acquisition differs from that of gefitinib when used clinically as first-line therapy re...

Full description

Bibliographic Details
Main Authors: Byung Woo Yoon, Jae Hoon Kim, Seung Hyeon Lee, Chang-Min Choi, Jin Kyung Rho, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim, Tae-Won Jang, Jae Cheol Lee
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319300245

Similar Items

Similar Items